Jenburkt Pharmaceuticals quarterly results and financials

Jenburkt Pharmaceuticals (JENBURPH)₹953.75−2.08%(9 Nov 2026 close)Pharmaceuticals

Key facts

In the Jun 2026 quarter (standalone), Jenburkt Pharmaceuticals reported sales of ₹35.50 Cr, down 0.2% from Jun 2025, and net profit of ₹5.90 Cr, down 24.4% year on year. For the year to Mar 2026, sales were ₹169 Cr and net profit ₹35.07 Cr.

Sales (Jun 2026): ₹35.50 Cr
Net profit (Jun 2026): ₹5.90 Cr
Sales (FY Mar 2026): ₹169 Cr
Net profit (FY Mar 2026): ₹35.07 Cr
EPS (Jun 2026): ₹13.33
Borrowings (Mar 2026): ₹1.99 Cr

Company filings, standalone accounts; latest reported quarter Jun 2026

Jenburkt Pharmaceuticals quarterly results

₹ crore unless stated; each column is a quarter.

Jenburkt Pharmaceuticals Quarterly results
	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	38.34	35.67	38.85	32.57	41.23	36.90	41.04	35.56	45.58	43.05	44.62	35.50
Expenses	29.26	28.55	29.04	23.32	29.86	28.16	30.26	26.63	32.51	35.66	30.48	29.54
Operating Profit	9.09	7.18	9.84	9.26	11.41	8.81	10.84	8.93	13.08	7.42	14.23	6.02
OPM %	23.8%	20.2%	25.4%	28.6%	27.8%	24.0%	26.5%	25.2%	28.8%	17.4%	32.0%	17.0%
Other Income	1.09	1.34	1.20	1.40	1.84	1.57	1.89	2.05	2.07	1.81	0.39	1.50
Interest	0.06	0.06	0.05	0.10	0.11	0.10	0.10	0.10	0.10	0.11	0.12	0.12
Depreciation	0.60	0.64	0.63	0.53	0.65	0.79	0.80	0.73	0.75	0.84	0.82	0.65
Profit before tax	9.58	7.88	10.40	10.11	12.57	9.55	11.89	10.22	14.40	8.33	13.77	6.80
Tax %	23.3%	31.1%	24.0%	26.4%	23.3%	31.7%	27.9%	23.5%	29.1%	28.5%	20.9%	13.0%
Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	−2.89	0.00
Net Profit	7.33	5.41	7.90	7.43	9.61	6.52	8.56	7.80	10.18	5.94	10.87	5.90
EPS (Rs)	16.56	12.22	17.82	16.77	21.71	14.73	19.32	17.63	22.97	13.41	24.54	13.33

Jenburkt Pharmaceuticals profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Jenburkt Pharmaceuticals Profit and loss
	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	94.01	103	115	123	119	109	124	137	142	152	169	169
Expenses	77.17	84.23	91.23	98.25	99.17	89.28	97.31	106	109	111	125	128
Operating Profit	15.98	19.97	23.95	24.97	19.96	19.98	26.96	29.97	32.96	39.94	43.94	40.75
OPM %	18.1%	19.1%	21.1%	20.1%	17.1%	18.0%	22.1%	22.0%	23.1%	27.1%	26.0%	24.2%
Other Income	2.99	2.99	3.01	2.99	4.01	4.01	4.99	4.99	5.01	7.01	5.99	5.77
Interest	0.00	0.00	0.00	0.00	0.99	0.00	0.00	0.00	0.00	0.00	0.00	0.45
Depreciation	2.01	2.01	2.01	1.01	2.01	2.01	2.01	2.01	2.01	3.01	3.01	3.06
Profit before tax	17.06	20.09	25.09	27.12	21.10	22.09	30.12	33.13	35.14	44.20	47.21	43.30
Tax %	36.0%	34.0%	32.0%	26.0%	30.0%	24.0%	25.0%	25.0%	26.0%	27.0%	25.0%	—
Exceptional items	0.00	0.09	0.02	−0.01	0.00	0.00	0.13	0.00	0.03	1.01	−2.60	−2.89
Net Profit	11.01	14.01	17.03	20.03	15.04	16.03	22.03	25.02	26.05	32.07	35.07	32.89
EPS (Rs)	23.17	29.03	37.44	43.07	32.35	35.91	48.51	55.64	58.74	72.51	78.61	74.25
Dividend payout %	30.9%	28.0%	24.0%	24.0%	24.9%	27.9%	25.0%	25.9%	25.9%	25.0%	26.0%	—

Jenburkt Pharmaceuticals balance sheet

₹ crore, at each year end.

Jenburkt Pharmaceuticals Balance sheet
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	4.99	4.99	5.00	4.99	4.99	4.99	4.99	5.00	3.99	4.00	3.99	3.99
Reserves	29.01	35.92	49.92	56.94	72.88	74.81	93.89	113	118	141	167	193
Borrowings	6.99	4.98	5.98	0.00	6.98	2.99	4.99	6.98	2.99	0.00	3.99	1.99
Other Liabilities	20.90	11.94	15.92	15.92	17.92	20.90	16.91	17.92	15.92	18.91	18.90	25.87
Total Liabilities	60.89	57.83	75.82	76.85	103	104	120	143	141	164	195	225
Fixed Assets	11.96	11.96	10.97	9.96	9.97	11.95	10.97	10.96	9.97	9.96	14.94	18.93
CWIP	0.00	0.00	0.00	0.00	1.01	0.00	0.00	0.00	1.01	1.01	40.11	46.12
Investments	0.00	0.99	1.99	4.99	4.98	3.99	6.98	7.97	10.97	16.96	20.94	26.92
Other Assets	48.93	44.88	63.86	61.90	86.81	87.75	103	123	119	136	120	132
Inventories	7.99	7.99	10.99	6.99	9.99	10.99	7.99	9.99	7.99	8.98	8.99	13.98
Trade receivables	7.02	6.02	9.03	13.04	23.06	18.07	14.06	15.04	17.05	19.07	21.08	24.06
Cash & equivalents	28.01	30.04	42.06	41.06	52.08	58.09	57.01	49.03	54.05	79.03	25.01	53.03
Total Assets	60.89	57.83	75.82	76.85	103	104	120	143	141	164	195	225

Jenburkt Pharmaceuticals cash flow

₹ crore, for each year.

Jenburkt Pharmaceuticals Cash flow
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	8.99	8.01	9.99	15.98	13.01	14.99	18.99	8.99	16.99	7.99	27.98	27.01
Cash from investing activity	1.01	0.00	−10.01	1.01	−11.01	−3.01	−19.03	−1.01	3.01	−1.01	−17.02	−19.01
Cash from financing activity	0.99	−4.98	0.99	−17.94	−1.99	−10.96	−0.99	−5.98	−20.92	−6.98	−7.97	−8.97
Net cash flow	10.98	1.99	0.99	−0.99	0.00	0.99	0.00	2.99	−0.99	0.00	2.99	−1.99
Capex	0.78	2.52	0.36	0.44	2.39	4.54	1.14	3.04	2.09	2.54	19.69	13.70
Free cash flow	7.97	4.98	9.97	15.93	10.96	10.95	17.94	6.97	14.94	5.98	7.97	12.96
CFO / OP %	88.1%	82.1%	85.1%	103.1%	80.1%	104.1%	127.1%	62.1%	83.0%	49.1%	102.0%	88.1%

Jenburkt Pharmaceuticals ratios

Working-capital days and returns, by year.

Jenburkt Pharmaceuticals Ratios
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	31	22	31	39	67	54	46	44	44	49	49	52
Inventory days	107	109	128	73	99	120	92	115	92	103	109	154
Days payable	54	44	72	44	66	58	56	83	67	75	100	91
Cash conversion cycle	86	89	90	70	102	118	84	78	71	79	60	116
Working capital days	−10	7	11	26	36	33	18	17	32	37	32	42
ROCE %	42.0%	40.0%	39.0%	42.0%	37.0%	26.0%	24.0%	26.0%	27.0%	26.0%	27.0%	27.0%

Jenburkt Pharmaceuticals: frequently asked questions

What are the latest quarterly results of Jenburkt Pharmaceuticals?

For the Jun 2026 quarter, Jenburkt Pharmaceuticals reported sales of ₹35.50 Cr, down 0.2% year on year and net profit of ₹5.90 Cr, down 24.4% year on year. The operating margin was 17.0%.

What is the annual revenue of Jenburkt Pharmaceuticals?

Jenburkt Pharmaceuticals' sales for the year to Mar 2026 were ₹169 Cr; over the last twelve months they were ₹169 Cr.

What is the net profit of Jenburkt Pharmaceuticals?

Net profit for the year to Mar 2026 was ₹35.07 Cr, and ₹32.89 Cr over the last twelve months. Earnings per share over the same trailing period were ₹74.25.

How much debt does Jenburkt Pharmaceuticals have?

Jenburkt Pharmaceuticals reported borrowings of ₹1.99 Cr at Mar 2026, against cash and equivalents of ₹53.03 Cr.

What is the free cash flow of Jenburkt Pharmaceuticals?

Cash from operations was ₹27.01 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹12.96 Cr.

Loading…